연구용
제품 번호: S1173
화학 구조
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| Sf9 cells | Function assay | 60 mins | Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay, IC50=1 nM | |||
| mouse BA/F3 cells | Proliferation assay | Antiproliferative activity against mouse BA/F3 cells transfected with EGFR E746_A750_del/T790M mutant, EC50=2 nM | ||||
| human HCC827 cells | Proliferation assay | 72 h | Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay, IC50=7 nM | |||
| human PC9 cells | Proliferation assay | Antiproliferative activity against growth-resistant human PC9 cells expressing EGFR E746_A750/T790M mutant, EC50=14 nM | ||||
| NCI-H1975 cells | Function assay | 2 h | Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay, IC50=0.023 μM | |||
| human 16HBE cells | Proliferation assay | 72 h | Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay, IC50=0.811 μM | |||
| human A431 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay, IC50=1.108 μM | |||
| human LoVo cells | Function assay | 2 h | Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay, IC50=1.18 μM | |||
| human 16HBE14o- cells | Cytotoxicity assay | 72 h | Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay, IC50=1.355 μM | |||
| human BEAS2B cells | Cytotoxicity assay | 72 h | Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay, IC50=1.811 μM | |||
| human A549 cells | Proliferation assay | 72 h | Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay, IC50=2.102 μM | |||
| human HL7702 cells | Proliferation assay | 72 h | Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay, IC50=2.73 μM | |||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 494.18 | 화학식 | C25H27ClN6O3 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 1213269-23-8 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | N/A | Smiles | CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl)OC | ||
|
In vitro |
DMSO
: 13 mg/mL
(26.3 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
EGFR (L858R)
(BaF3 cells) 2 nM
EGFR (L858R/T790M)
(BaF3 cells) 8 nM
|
|---|---|
| 시험관 내(In vitro) |
WZ4002 inhibits other EGFR genotypes E746_A750 and E746_A750/T790M with IC50 of 2 and 6 nM. Besides, this compound suppresses widetype ERBB2 with an IC50 of 32 nM. It inhibits EGFR, AKT and ERK1/2 phosphorylation in NSCLC cell lines and prevents of EGFR phosphorylation in NIH-3T3 cells expressing different EGFR T790M mutant alleles. For this chemical, kinases that exhibited greater than 95% inhibition relative to the DMSO control at 10 μM are selected for measurement of their dissociation constants. This inhibitor, which possesses an ortho-methoxy group at the C2-aniline substituent, is more selective for EGFR compared to WZ3146. It is 100-fold less effective at inhibiting phosphorylation of WT EGFR compared to the quinazoline inhibitors. Similarly, this compound prevents EGFR kinase activity of recombinant L858R/T790M protein more potently than of WT EGFR, while the opposite is observed with HKI-272 and gefitinib. In addition, the phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, is completely suppressed by the third generation EGFR TKI, WZ4002.
|
| 키나아제 분석 |
EGFR 키나아제 분석
|
|
재조합 EGFR L858R/T790M 및 WT 단백질을 이용한 in vitro 효소 억제 동역학 분석은 96-well 형식에서 ATP/NADH 결합 분석 시스템을 사용하여 수행됩니다. WZ4002를 첨가하여 Protein Tyrosine Kinase에 대한 억제 효과를 확인합니다.
|
|
| 생체 내(In vivo) |
In a 2-week efficacy study, WZ4002 treatment results in significant tumor regressions compared to vehicle alone in both T790M containing murine models. Treatment with low-dose of this compound, and high-dose of this compound leads to mean decreases in tracer uptake of 26%, and 36%, respectively.
|
참조 |
|